388 related articles for article (PubMed ID: 31830233)
41. Phase I/II trials of
Denis-Bacelar AM; Chittenden SJ; Dearnaley DP; Divoli A; O'Sullivan JM; McCready VR; Johnson B; Du Y; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):620-629. PubMed ID: 27770145
[TBL] [Abstract][Full Text] [Related]
42. Practical guide to the use of radium 223 dichloride.
Den RB; Doyle LA; Knudsen KE
Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
[TBL] [Abstract][Full Text] [Related]
43. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
44. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
Winter BM; von Rundstedt FC; Grimm MO
Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
[TBL] [Abstract][Full Text] [Related]
45. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
46. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
[TBL] [Abstract][Full Text] [Related]
48. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
[TBL] [Abstract][Full Text] [Related]
49. Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
Blas L; Shiota M; Matsumoto T; Hori Y; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Nov; 30(11):1029-1034. PubMed ID: 37501328
[TBL] [Abstract][Full Text] [Related]
50. Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan.
Weng WC; Huang LH; Tseng NC; Ou YC
J Formos Med Assoc; 2022 Oct; 121(10):1929-1937. PubMed ID: 35123846
[TBL] [Abstract][Full Text] [Related]
51. Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Bouman-Wammes EW; de Klerk JMH; Bloemendal HJ; Van Dodewaard-de Jong JM; Lange R; Ter Heine R; Verheul HMW; Van den Eertwegh AJM
Clin Genitourin Cancer; 2019 Apr; 17(2):e281-e292. PubMed ID: 30555024
[TBL] [Abstract][Full Text] [Related]
52. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
53. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.
McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S
Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628
[TBL] [Abstract][Full Text] [Related]
54. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
55. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
56. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ali A; Hoyle A; Haran ÁM; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Dearnaley D; Attard G; Gillessen S; Parmar MKB; Parker CC; Sydes MR; James ND; Clarke NW
JAMA Oncol; 2021 Apr; 7(4):555-563. PubMed ID: 33599706
[TBL] [Abstract][Full Text] [Related]
57. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
58. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
[TBL] [Abstract][Full Text] [Related]
60. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
